Trading of Barinthus Biotherapeutics was halted at 11:04 AM EST due to "LULD pause". Barinthus Biotherapeutics (BRNS) Institutional Ownership $1.84 +0.82 (+80.49%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Barinthus Biotherapeutics (NASDAQ:BRNS)CurrentInstitutional OwnershipPercentage25.20%Number ofInstitutional Buyers(last 12 months)6TotalInstitutional Inflows(last 12 months)$2.93MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$243.66K Get BRNS Insider Trade Alerts Want to know when executives and insiders are buying or selling Barinthus Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data BRNS Institutional Buying and Selling by Quarter Barinthus Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/13/2025Gilead Sciences Inc.369,855$360K0.0%-40.4%0.917% 5/13/2025HighTower Advisors LLC37,450$36K0.0%N/A0.093% 2/14/2025Gilead Sciences Inc.620,351$749K0.0%N/A1.542% 8/2/2024Alphabet Inc.1,513,644$2.12M0.1%N/A3.878% 7/24/2024Catalina Capital Group LLC17,819$25K0.0%N/A0.046% 7/16/2024Ipswich Investment Management Co. Inc.23,075$32K0.0%N/A0.059% 7/16/2024M&G Plc5,197,349$7.28M0.0%N/A13.316% 5/16/2024BlueCrest Capital Management Ltd542,673$1.29M0.1%N/A1.394% 5/14/2024DC Funds LP642,204$1.53M14.8%N/A1.650% (Data available from 1/1/2016 forward) BRNS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of BRNS shares? During the previous two years, the following institutional investors and hedge funds held shares of Barinthus Biotherapeutics shares: M&G Plc ($7.28M), Alphabet Inc. ($2.12M), DC Funds LP ($1.53M), BlueCrest Capital Management Ltd ($1.29M), Gilead Sciences Inc. ($360K), HighTower Advisors LLC ($36K), and Ipswich Investment Management Co. Inc. ($32K).Learn more on Barinthus Biotherapeutics' institutional investors. What percentage of Barinthus Biotherapeutics' stock is owned by institutional investors? 25.20% of Barinthus Biotherapeutics' stock is owned by institutional investors. Learn more on BRNS's institutional investor holdings. Which institutional investors have been buying Barinthus Biotherapeutics' stock? The following institutional investors have purchased Barinthus Biotherapeutics' stock in the last 24 months: M&G Plc ($5.20M), Alphabet Inc. ($1.51M), DC Funds LP ($642.20K), Gilead Sciences Inc. ($620.35K), BlueCrest Capital Management Ltd ($542.67K), HighTower Advisors LLC ($37.45K), and Ipswich Investment Management Co. Inc. ($23.08K). How much institutional buying is happening at Barinthus Biotherapeutics? Institutional investors have bought a total of 2,189,264 shares in the last 24 months. This purchase volume represents approximately $2.93M in transactions. Which of Barinthus Biotherapeutics' major shareholders have been selling company stock? The following institutional investors have sold Barinthus Biotherapeutics stock in the last 24 months: Gilead Sciences Inc. ($250.50K). How much institutional selling is happening at Barinthus Biotherapeutics? Institutional investors have sold a total of 250,496 shares in the last 24 months. This volume of shares sold represents approximately $243.66K in transactions. Related Companies NVCT Institutional Ownership BIVI Institutional Ownership ACRS Institutional Ownership UPXI Institutional Ownership DMAC Institutional Ownership TIL Institutional Ownership ALEC Institutional Ownership CGEN Institutional Ownership IKT Institutional Ownership CRBU Institutional Ownership This page (NASDAQ:BRNS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BRNS Stock Alerts